Since short-term liver-targeted Angptl3 and Angptl4 silencing potently attenuated hyperlipidemia, we next assessed to what extent these treatments would also reduce atherosclerosis development over a treatment period of 12 weeks. The gene discussed is ANGPTL4; the disease is hyperlipidemia.